NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) posted a first quarter
net loss attributable to Bristol Myers Squibb of $11.9 billion, or $5.89 per
share, compared to net income of $2.3 billion, or $1.07 per share, a year ago.
On a non-GAAP basis, net loss attributable to Bristol Myers Squibb was $8.9
billion, or $4.40 per share, compared to net profit of $4.3 billion, or $2.05
per share, last year. On average, 17 analysts polled by Thomson Reuters expected
the company to report a loss per share of $4.44, for the quarter. Analysts'
estimates typically exclude special items.

Net product sales were $11.56 billion compared to $11.05 billion, last year.
Revenues were $11.9 billion, an increase of 5% or 6% when adjusted for foreign
exchange impacts, primarily driven by Eliquis, Reblozyl and Opdualag, partially
offset by Opdivo and Revlimid. Analysts on average had estimated $11.46 billion
in revenue. U.S. revenues increased 7% to $8.5 billion.

Bristol Myers Squibb updated portions of its 2024 line-item guidance, including
non-GAAP EPS, to reflect the impact of recent transactions. Total deals impact
was $6.73. As a result, revised non-GAAP EPS guidance is $0.40 - $0.70. Analysts
expect the company to report profit per share of $0.65.

For more earnings news, earnings calendar, and earnings for stocks, visit
rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX